AR112902A1 - Receptores de células t restringidas a hla de clase ii contra ras mutado - Google Patents

Receptores de células t restringidas a hla de clase ii contra ras mutado

Info

Publication number
AR112902A1
AR112902A1 ARP180102695A ARP180102695A AR112902A1 AR 112902 A1 AR112902 A1 AR 112902A1 AR P180102695 A ARP180102695 A AR P180102695A AR P180102695 A ARP180102695 A AR P180102695A AR 112902 A1 AR112902 A1 AR 112902A1
Authority
AR
Argentina
Prior art keywords
restricted
hla class
cell receptors
tcr
mammal
Prior art date
Application number
ARP180102695A
Other languages
English (en)
Original Assignee
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Health filed Critical Us Health
Publication of AR112902A1 publication Critical patent/AR112902A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4244—Enzymes
    • A61K40/4253—GTPases, e.g. Ras or Rho
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57575—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7023—(Hyper)proliferation
    • G01N2800/7028—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)

Abstract

Se describe un receptor de células T aislado o purificado (TCR), en donde el TCR tiene especificidad antigénica para el homólogo de oncogén viral de sarcoma de rata Kirsten mutado (KRAS) presentado por una molécula de clase II de antígeno leucocitario humano (HLA). También se proporcionan proteínas y polipéptidos relacionados, así como ácidos nucleicos, vectores de expresión recombinantes, células huésped, poblaciones de células y composiciones farmacéuticas relacionados. También se describen métodos para detectar la presencia de cáncer en un mamífero y métodos para tratar o prevenir el cáncer en un mamífero.
ARP180102695A 2017-09-20 2018-09-20 Receptores de células t restringidas a hla de clase ii contra ras mutado AR112902A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762560930P 2017-09-20 2017-09-20

Publications (1)

Publication Number Publication Date
AR112902A1 true AR112902A1 (es) 2019-12-26

Family

ID=63963389

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP180102695A AR112902A1 (es) 2017-09-20 2018-09-20 Receptores de células t restringidas a hla de clase ii contra ras mutado

Country Status (17)

Country Link
US (3) US11306132B2 (es)
EP (1) EP3684799A1 (es)
JP (1) JP7256794B2 (es)
KR (2) KR20250037592A (es)
CN (2) CN120082603A (es)
AR (1) AR112902A1 (es)
AU (2) AU2018335274B2 (es)
BR (1) BR112020005469A2 (es)
CA (1) CA3076339A1 (es)
CR (1) CR20240019A (es)
EA (1) EA202090652A1 (es)
IL (1) IL273254B2 (es)
MA (1) MA50180A (es)
MX (2) MX2020003117A (es)
SG (1) SG11202002425PA (es)
TW (1) TWI825029B (es)
WO (1) WO2019060349A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201700621D0 (en) 2017-01-13 2017-03-01 Guest Ryan Dominic Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue
WO2020154617A1 (en) * 2019-01-25 2020-07-30 The Trustees Of The University Of Pennsylvania Compositions and methods for targeting mutant ras
US20220291215A1 (en) * 2019-07-30 2022-09-15 University Health Network Methods of identifying t cell receptors
CN112759641B (zh) * 2019-11-01 2023-01-20 香雪生命科学技术（广东）有限公司 一种识别Kras G12V的高亲和力TCR
BR112022011795A2 (pt) 2019-12-20 2022-08-30 Instil Bio Uk Ltd Métodos para preparar e isolar uma população terapêutica de linfócitos e para tratar câncer em um indivíduo, população terapêutica de linfócitos, bolsa criopreservada, recipiente flexível, e, sistema para extração de linfócitos
KR20220143875A (ko) * 2020-02-14 2022-10-25 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 G12v 돌연변이를 갖는 ras에 대한 hla 클래스 i-제한된 t 세포 수용체
CA3170658A1 (en) * 2020-02-19 2021-08-26 Aelin Therapeutics Molecules targeting mutant ras protein
EP4110804A1 (en) * 2020-02-26 2023-01-04 The United States of America, as represented by the Secretary, Department of Health and Human Services Hla class ii-restricted t cell receptors against ras with g12v mutation
WO2021262829A2 (en) * 2020-06-24 2021-12-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hla class i-restricted t cell receptors against cd20
EP4178976A1 (en) * 2020-07-13 2023-05-17 The United States of America, as represented by the Secretary, Department of Health and Human Services Hla class ii?restricted drb t cell receptors against ras with g12d mutation
AU2021309958A1 (en) * 2020-07-16 2023-02-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services HLA class II-restricted DRB T cell receptors against RAS with G12V mutation
CN112300269B (zh) * 2020-09-29 2022-12-09 中国科学院微生物研究所 Kras突变特异性t细胞受体筛选及抗肿瘤用途
TW202229327A (zh) * 2020-10-02 2022-08-01 美國衛生與公眾服務部 針對含有g13d突變之ras之hla第ii類限制性dq t細胞受體
US20240000834A1 (en) * 2020-11-24 2024-01-04 Shanghai GenBase Biotechnology Co., Ltd. Ras mutant epitope peptide and t cell receptor recognizing ras mutant
WO2022183167A1 (en) 2021-02-25 2022-09-01 Alaunos Therapeutics, Inc. Recombinant vectors comprising polycistronic expression cassettes and methods of use thereof
US20250145950A1 (en) 2022-02-01 2025-05-08 Alaunos Therapeutics, Inc. Methods for Activation and Expansion of T Cells
CN114835800B (zh) * 2022-05-27 2023-10-13 重庆医科大学 Tcr或其抗原结合片段及其应用
CN117264043B (zh) * 2022-06-14 2024-05-10 上海镔铁生物科技有限责任公司 靶向kras g12v突变多肽的t细胞受体及其用途
WO2024072954A1 (en) * 2022-09-29 2024-04-04 Jerome Canady Research Institute for Advanced Biological and Technological Sciences Cold atmopsheric plasma treated pan-cancer epitope peptide within the collagen type vi a-3 (col6a3) protein as cancer vaccine
WO2026019786A1 (en) * 2024-07-16 2026-01-22 Board Of Regents, The University Of Texas System Peptides and engineered t cell receptors targeting brachyury antigen and methods of use
WO2026024602A2 (en) * 2024-07-22 2026-01-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors against ras with g12d, g12v, g13d or q61r mutation

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8034334B2 (en) 2002-09-06 2011-10-11 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Immunotherapy with in vitro-selected antigen-specific lymphocytes after non-myeloablative lymphodepleting chemotherapy
GB0328363D0 (en) * 2003-12-06 2004-01-14 Imp College Innovations Ltd Therapeutically useful molecules
US8383099B2 (en) 2009-08-28 2013-02-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adoptive cell therapy with young T cells
US20120244133A1 (en) 2011-03-22 2012-09-27 The United States of America, as represented by the Secretary, Department of Health and Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
AU2014407539B2 (en) 2014-10-02 2020-10-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of isolating T cell receptors having antigenic specificity for a cancer-specific mutation
CN118994363A (zh) * 2014-11-26 2024-11-22 美国卫生和人力服务部 抗突变的kras的t细胞受体
WO2017015562A1 (en) * 2015-07-22 2017-01-26 Araxes Pharma Llc Substituted quinazoline compounds and their use as inhibitors of g12c mutant kras, hras and/or nras proteins
ES2879287T3 (es) * 2015-09-15 2021-11-22 Us Health Receptores de células T que reconocen KRAS mutado restringido a HLA-cw8
HRP20221183T1 (hr) 2016-08-02 2022-12-09 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services T-stanični receptori anti-kras-g12d

Also Published As

Publication number Publication date
TW201920251A (zh) 2019-06-01
CN111201237B (zh) 2025-03-25
US20250250318A1 (en) 2025-08-07
KR20200051804A (ko) 2020-05-13
CN120082603A (zh) 2025-06-03
CN111201237A (zh) 2020-05-26
US20190085046A1 (en) 2019-03-21
IL273254B2 (en) 2024-09-01
SG11202002425PA (en) 2020-04-29
KR20250037592A (ko) 2025-03-17
TWI825029B (zh) 2023-12-11
IL273254B1 (en) 2024-05-01
AU2025202532A1 (en) 2025-05-01
MA50180A (fr) 2021-05-26
IL273254A (en) 2020-04-30
AU2018335274A1 (en) 2020-04-09
MX2024004610A (es) 2024-04-30
JP2020534828A (ja) 2020-12-03
MX2020003117A (es) 2020-08-20
EP3684799A1 (en) 2020-07-29
KR102777370B1 (ko) 2025-03-10
EA202090652A1 (ru) 2020-08-21
CR20240019A (es) 2024-02-15
BR112020005469A2 (pt) 2020-09-29
US12304940B2 (en) 2025-05-20
WO2019060349A1 (en) 2019-03-28
AU2025202532A9 (en) 2025-09-04
CA3076339A1 (en) 2019-03-28
AU2018335274B2 (en) 2025-02-13
US20220204584A1 (en) 2022-06-30
JP7256794B2 (ja) 2023-04-12
US11306132B2 (en) 2022-04-19

Similar Documents

Publication Publication Date Title
AR112902A1 (es) Receptores de células t restringidas a hla de clase ii contra ras mutado
MX2020005765A (es) Receptores de celulas t restringidos a antigeno leucocitario humano (hla) clase i contra sarcoma de rata (ras) mutado.
CY1125601T1 (el) Υποδοχεις anti-kras-g12d κυτταρων τ
MX2018003062A (es) Receptores de celula t que reconocen kras mutante restringido en hla-cw8.
MX2017006865A (es) Receptores de células t de kras anti-mutado.
MX2020003504A (es) Receptores de celulas t que reconocen p53 mutado.
CY1122720T1 (el) Υποδοχεις τ κυτταρων που αναγνωριζουν περιορισμενη μαgε-α3 μηc ταξης ii
MX2020010035A (es) Receptores de celulas t anti-papilomavirus 16 e7 humano.
CL2022003264A1 (es) Péptidos y sus combinaciones para uso en inmunoterapia contra el cáncer de próstata y otros
CY1124176T1 (el) Προβλεψη ανοσογονiκοτητας των επιτοπων των t κυτταρων
SA519410362B1 (ar) مستقبل للخلايا التائية (tcr) وببتيدات
CL2020001181A1 (es) Nuevos receptores de células t modificados genéticamente y terapias inmunológicas que emplean los mismos.
MX2021011613A (es) Receptores de células t de mage a4.
CY1118072T1 (el) Συζευγματα cc-1065 αναλογων και διλειτουργικων αρθρωτων
MX2021015877A (es) Receptores de celulas t que reconocen la mutacion r175h o y220c en p53.
BR112019007100A2 (pt) composições e métodos para reprogramação de receptores de célula t com o uso de proteínas de fusão
MX421741B (es) Inmunoterapia con receptores de antígeno quimérico y uso de la misma
CY1123520T1 (el) Μεθοδοι για την προβλεψη της χρησιμοτητας των νεων αντιγονων για ανοσοθεραπεια
EA202090931A3 (ru) Композиции и способы перепрограммирования tcr с помощью гибридных белков
CL2022002208A1 (es) Receptor de células t restringido por hla de la clase i contra ras con mutación
MX2021002225A (es) Composiciones y metodos para la reprogramacion de tcr mediante el uso de proteinas de fusion.
TR201905447T4 (tr) Yeni mhc bağımsız tümörle ilişkili antijenler.
CY1125328T1 (el) Ανασυνδυασμενο εμβολιο ιου λευχαιμιας αιλουροειδων περιεχοντας βελτιστοποιημενο γονιδιο φακελου ιου λευχαιμιας αιλουροειδων